Continuous intravenous vancomycin in children with normal renal function hospitalized in hematology ‐oncology: prospective validation of a dosing regimen optimizing steady‐state concentration

This study assessed the prospective validation of this age‐based nomogram and the influence on Css attainment of variables as the gender, underlying disease (oncology or hematology), and hematopoietic stem cell transplantation (HSCT) before receiving vancomycin therapy. A total of 94 patients aged from 4.3 months to 17.9 years old with normal renal function were eligible for the prospective validation. Fifty‐five of those patients (58.5%) achieved the target range of vancomycin Css. There was no significant difference between age groups (p=0.816) and no influence of gender (p=0.500). There was a non‐significant trend to a better target attainment in oncology patients (69.2% vs. hematology 54.4%, p=0.142) and patients who did not undergo HSCT (63.3% vs. 33.3%, p=0.031). This study proposed an age‐based nomogram prospectively validated which near 60% of patients of each age class achieving the target range of Css. This article is protected by copyright. All rights reserved.
Source: Fundamental and Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Original Article Source Type: research